எலிசபெத் பாக்ஸ்டர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Roche receives FDA authorisation for testing of asymptomatic people with the cobas SARS-CoV-2 Test to help control the spread of COVID-19 The high-throughput, highly sensitive cobas SARS-CoV-2 Test under FDA Emergency Use Authorisation can now be used to test individual or pooled samples from people without symptoms or other reasons to suspect COVID-19 Accurate, reliable and early detection of SARS-CoV-2 in potentially exposed individuals can help limit the spread of disease PLEASANTON, Calif., May 18, 2021 /PRNewswire/ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Test for use on the widely available, high-throughput cobas 6800/8800 Systems has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for testing individuals without symptoms or reasons to suspect COVID-19. This authorisation supports the guidance update from the U.S. Centers for Disease Control and Prevention (CDC) to expand SARS-CoV

United statesMike weistElizabeth baxterCindy perettieCenters for diseaseUs centers for diseaseHead of molecular labWorld health organizationDrug administrationRoche diagnostics solutionsClinical laboratory improvement amendmentsRoche groupPharmaceuticals industryDrug administration emergency use authorizationUse authorisationEmergency use authorisation